Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04314999
Other study ID # 2019-01953;sp20Steveling2
Secondary ID
Status Completed
Phase
First received
Last updated
Start date June 1, 2019
Est. completion date September 30, 2019

Study information

Verified date March 2020
Source University Hospital, Basel, Switzerland
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The goal of this study is to describe the prevalence and the type of parasite in patients with a chronic spontaneous urticaria as well as to describe the associations between parasitic disease and the characteristics of the patients, for example eosinophilia.


Recruitment information / eligibility

Status Completed
Enrollment 57
Est. completion date September 30, 2019
Est. primary completion date September 30, 2019
Accepts healthy volunteers
Gender All
Age group 17 Years and older
Eligibility Inclusion Criteria:

- Diagnosis of a chronic spontaneous urticaria

- Age: 17 years old and up

Exclusion Criteria:

- No diagnosis of a chronic spontaneous urticaria

- Age: younger than 17 years

Study Design


Intervention

Diagnostic Test:
Examination of stool samples
Tests for diagnosis of parasitic diseases

Locations

Country Name City State
Switzerland University Hospital Basel Basel

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Basel, Switzerland

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of patients with parasite infestation assess number of patients with chronic spontaneous urticaria that have a parasite infestation (Analysis of stool samples by the Swiss Tropical and Public Health Institute (TPH), Basel) Patients with a chronic spontaneous urticaria that were treated at the University hospital basel between the 1st of June 2019 and the 30th of September 2019
Primary Most common parasite subgroup subtype determination from stool samples was performed by the Swiss TPH, Basel by polymerase chain reaction (PCR) Patients with a chronic spontaneous urticaria that were treated at the University hospital basel between the 1st of June 2019 and the 30th of September 2019
Secondary Correlation between migration Background/ travel history of the patients and parasite infestation examine travel history and migration background of patients Patients with a chronic spontaneous urticaria that were treated at the University hospital basel between the 1st of June 2019 and the 30th of September 2019
Secondary Correlation between gastrointestinal complaints of the patients and parasite infestation anamnesis of the patients Patients with a chronic spontaneous urticaria that were treated at the University hospital basel between the 1st of June 2019 and the 30th of September 2019
See also
  Status Clinical Trial Phase
Recruiting NCT06077773 - Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria Phase 2
Completed NCT04538794 - A Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria Phase 1
Completed NCT01803763 - Prospective Double-blind Placebo-controlled Study of the Effect of Xolair (Omalizumab) in Chronic Urticaria Patients Phase 2/Phase 3
Recruiting NCT05298215 - A Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Efficacy of UB-221 IV Infusion as an add-on Therapy in Patients With Chronic Spontaneous Urticaria Phase 2
Terminated NCT04612725 - A Study to Investigate the Use of Benralizumab in Patients With Chronic Spontaneous Urticaria Who Are Symptomatic Despite the Use of Antihistamines (ARROYO) Phase 2
Terminated NCT05528861 - A Study to Assess Subcutaneous Lirentelimab (AK002) in Chronic Spontaneous Urticaria Phase 2
Completed NCT04109313 - An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of LOU064 in Subjects With CSU Phase 2
Completed NCT03580356 - A Phase III Study of and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines. Phase 3
Completed NCT03580369 - A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines Phase 3
Completed NCT05030311 - A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1 Antihistamines Phase 3
Recruiting NCT06162728 - Dose Escalation Trial Of Safety, Pharmacokinetic/Pharmacodynamic And Preliminary Clinical Activity of Briquilimab In Adult Patients With Chronic Spontaneous Urticaria (CSU) Phase 1/Phase 2
Completed NCT05107115 - Rilzabrutinib for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine Phase 2
Recruiting NCT06042478 - A Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo and With Omalizumab as Active Control in CSU Adult Patients. Phase 3
Terminated NCT04159701 - A Study of LY3454738 in Adults With Chronic Spontaneous Urticaria Phase 2
Completed NCT03749135 - Dupilumab in Chronic Spontaneous Urticaria Phase 2
Not yet recruiting NCT06396026 - A Study of Efficacy and Safety of TLL-018 in CSU Participants Phase 3
Completed NCT02649218 - A Safety Extension Study to Evaluate the Long-term Safety of QGE031 in Chronic Spontaneous Urticaria (CSU) Patients Phase 2
Active, not recruiting NCT05368285 - A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria Phase 2
Completed NCT05373355 - Safety and Efficacy of TLL018 in Patients With Chronic Spontaneous Urticaria. Phase 1
Not yet recruiting NCT06365879 - To Compare Efficacy and Safety of CMAB007 and Xolair® in Patients With Chronic Spontaneous Urticaria Phase 3